TY - JOUR T1 - Diagnosis of COVID-19 Using CT image Radiomics Features: A Comprehensive Machine Learning Study Involving 26,307 Patients JF - medRxiv DO - 10.1101/2021.12.07.21267367 SP - 2021.12.07.21267367 AU - Isaac Shiri AU - Yazdan Salimi AU - Abdollah Saberi AU - Masoumeh Pakbin AU - Ghasem Hajianfar AU - Atlas Haddadi Avval AU - Amirhossein Sanaat AU - Azadeh Akhavanallaf AU - Shayan Mostafaei AU - Zahra Mansouri AU - Dariush Askari AU - Mohammadreza Ghasemian AU - Ehsan Sharifipour AU - Saleh Sandoughdaran AU - Ahmad Sohrabi AU - Elham Sadati AU - Somayeh Livani AU - Pooya Iranpour AU - Shahriar Kolahi AU - Bardia Khosravi AU - Maziar Khateri AU - Salar Bijari AU - Mohammad Reza Atashzar AU - Sajad P. Shayesteh AU - Mohammad Reza Babaei AU - Elnaz Jenabi AU - Mohammad Hasanian AU - Alireza Shahhamzeh AU - Seyed Yaser Foroghi Gholami AU - Abolfazl Mozafari AU - Hesamaddin Shirzad-Aski AU - Fatemeh Movaseghi AU - Rama Bozorgmehr AU - Neda Goharpey AU - Hamid Abdollahi AU - Parham Geramifar AU - Amir Reza Radmard AU - Hossein Arabi AU - Kiara Rezaei-Kalantari AU - Mehrdad Oveisi AU - Arman Rahmim AU - Habib Zaidi Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/08/2021.12.07.21267367.abstract N2 - Purpose To derive and validate an effective radiomics-based model for differentiation of COVID-19 pneumonia from other lung diseases using a very large cohort of patients.Methods We collected 19 private and 5 public datasets, accumulating to 26,307 individual patient images (15,148 COVID-19; 9,657 with other lung diseases e.g. non-COVID-19 pneumonia, lung cancer, pulmonary embolism; 1502 normal cases). Images were automatically segmented using a validated deep learning (DL) model and the results carefully reviewed. Images were first cropped into lung-only region boxes, then resized to 296×216 voxels. Voxel dimensions was resized to 1×1×1mm3 followed by 64-bin discretization. The 108 extracted features included shape, first-order histogram and texture features. Univariate analysis was first performed using simple logistic regression. The thresholds were fixed in the training set and then evaluation performed on the test set. False discovery rate (FDR) correction was applied to the p-values. Z-Score normalization was applied to all features. For multivariate analysis, features with high correlation (R2>0.99) were eliminated first using Pearson correlation. We tested 96 different machine learning strategies through cross-combining 4 feature selectors or 8 dimensionality reduction techniques with 8 classifiers. We trained and evaluated our models using 3 different datasets: 1) the entire dataset (26,307 patients: 15,148 COVID-19; 11,159 non-COVID-19); 2) excluding normal patients in non-COVID-19, and including only RT-PCR positive COVID-19 cases in the COVID-19 class (20,697 patients including 12,419 COVID-19, and 8,278 non-COVID-19)); 3) including only non-COVID-19 pneumonia patients and a random sample of COVID-19 patients (5,582 patients: 3,000 COVID-19, and 2,582 non-COVID-19) to provide balanced classes. Subsequently, each of these 3 datasets were randomly split into 70% and 30% for training and testing, respectively. All various steps, including feature preprocessing, feature selection, and classification, were performed separately in each dataset. Classification algorithms were optimized during training using grid search algorithms. The best models were chosen by a one-standard-deviation rule in 10-fold cross-validation and then were evaluated on the test sets.Results In dataset #1, Relief feature selection and RF classifier combination resulted in the highest performance (Area under the receiver operating characteristic curve (AUC) = 0.99, sensitivity = 0.98, specificity = 0.94, accuracy = 0.96, positive predictive value (PPV) = 0.96, and negative predicted value (NPV) = 0.96). In dataset #2, Recursive Feature Elimination (RFE) feature selection and Random Forest (RF) classifier combination resulted in the highest performance (AUC = 0.99, sensitivity = 0.98, specificity = 0.95, accuracy = 0.97, PPV = 0.96, and NPV = 0.98). In dataset #3, the ANOVA feature selection and RF classifier combination resulted in the highest performance (AUC = 0.98, sensitivity = 0.96, specificity = 0.93, accuracy = 0.94, PPV = 0.93, NPV = 0.96).Conclusion Radiomic features extracted from entire lung combined with machine learning algorithms can enable very effective, routine diagnosis of COVID-19 pneumonia from CT images without the use of any other diagnostic test.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swiss National Science Foundation under grant SNRF 320030_176052.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves openly and private data human data, which for private data approved by institutional review boards (IRBs) of Shahid Beheshti University of Medical Sciences, Alborz University of Medical Sciences and Tehran University of Medical Sciences, Iran, and written informed consent of patients was waived by the ethics committees as anonymized data were used without any interventional effect on diagnosis, treatment or management of COVID-19 patients Openly data can be obtained from: https://www.cancerimagingarchive.net/collections/ https://mosmed.ai/datasets/covid19_1110 http://ictcf.biocuckoo.cn/HUST-19.php https://www.rsna.org/education/ai-resources-and-training/ai-image-challengeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://www.cancerimagingarchive.net/collections/ https://mosmed.ai/datasets/covid19_1110 http://ictcf.biocuckoo.cn/HUST-19.php https://www.rsna.org/education/ai-resources-and-training/ai-image-challenge ER -